New open letter from Gilead CEO on remdesivir data: “We recognize the limitations of these compassionate use data from a purely investigational perspective, while knowing they are of the greatest significance for the patients whose symptoms improved. gilead.com/stories/articl…
Gilead CEO Dan O’Day: “The results, which cover 53 of the first patients to have been treated in the program, show that the majority demonstrated clinical improvement after taking remedesivir.”
Also notes 7 clinical trials initiated,data expected end of April in severe #COVID19
Also notes 7 clinical trials initiated,data expected end of April in severe #COVID19
O’Day: “With every day that goes by, the desperate need to equip healthcare workers and their patients with a safe, effective treatment becomes more pressing. We are working with intense speed to determine whether remdesivir could be an option...”
Gilead details upcoming remdesivir trial readouts:
End of April: Gilead trial in severe #COVID19
China trials up to Chinese investigators (severe pt trial was stopped due to stalled enrollment)
May: Initial data from NIAID trial; Gilead’s trial in pts w moderate symptoms
End of April: Gilead trial in severe #COVID19
China trials up to Chinese investigators (severe pt trial was stopped due to stalled enrollment)
May: Initial data from NIAID trial; Gilead’s trial in pts w moderate symptoms
